Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD

Thorax

Volumn 58, Issue 7, 2003, Pages 573-579

  Profita, M ^b   Chiappara, G ^b   Mirabella, F ^b   Di Giorgi, R ^b   Chimenti, L ^b   Costanzo, G ^b   Riccobono, L ^b   Bellia, V ^a   Bousquet, J ^c   Vignola, A M ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CILOMILAST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; CELL CULTURE; CELL ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; INFLAMMATION; MALE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL;

ADULT; AGED; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; CELL COUNT; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; NITRILES; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; SPUTUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038353483     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.7.573     Document Type: Article

References (35)

1. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998;53:129-36.
2. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001;7:55-62.
3. Churg A, Dai J, Tai H, et al. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002;166:849-54.
4. 1-antitrypsin deficiency and the role of leukotriene B4 and interleukin 8. Thorax 2002;57:709-14.
5. Keatings V, Collins P, Scott D, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
6. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999;54:825-57.
7. Vignola AM, Chanez P, Chiappara G, et al. Transforming growth factor-β expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997;156:591-9.
8. Gagliardo R, Chanez P, Vignola AM, et al. Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med 2000;162:7-13.
9. Balbi B, Bason C, Balleari E, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846-50.
10. Torphy TJ, Barnette MS, Hay DW, et al. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ Health Perspect 1994;10:79-84.
11. Haddad JJ, Land SC, Tarnow-Mordi WO, et al. Immunopharmacological potential of selective phasphodiesterase inhibition. I. Diffrencial regulation of lipopolysaccaride-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002;300:559-66.
12. Wright LC, Seybold J, Robichaud A, et al. Phosphodiesterase expression in human epithelial cells. Am J Physiol 1998;275:L694-700.
13. Fuhrmann M, Jahn HU, Seybold J, et al. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 1999;20:292-302.
14. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990;11:150-5.
15. Torphy TJ, Barnette MS, Underwood DC, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5.
16. Griswold DE, Webb EF, Badger AM, et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998;287:705-11.
17. Spond J, Chapman R, Fine J, et al. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 2001;14:157-64.
18. Souza DG, Cassali GD, Poole S, et al. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury. Br J Pharmacol 2001;134:985-94.
19. Pauwel RA, Buist AS, Calverley PMA, et al. Global straetgy for the diagnosis, managment and prevention of COPD. NHLBI/WHO Global Initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
20. Vignola AM, Campbell AM, Chanez P, et al. Activation by histamine of bronchial epithelial cells from nonasthmatic subjects. Am J Respir Cell Mol Biol 1993;9:411-7.
21. Hargreave FE, Popov T, Kidney J, et al. Sputum measurements to assess airway inflammation in asthma. Allergy 1993;48(17 Suppl):81-3.
22. Profita M, Sala A, Riccobono L, et al. 15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol 2000;279:C1249-58.
23. Pace E, Gjomarkaj M, Melis M, et al. Interleukin-8 induces Lumphocyte chemotaxis into the pleural space. Am J Respir Crit Care Med 1999;159:1592-9.
24. Bloemen PG, van den Tweel MC, Henricks PA, et al. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 1997;272:L580-7.
25. Koyama S, Rennard SI, Claassen L, et al. Dibutyryl cAMP, prostaglandin E2, and antioxidants protect cultured bovine bronchial epithelial cells from endotoxin. Am J Physiol 1991;261:L126-32.
26. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-70.
27. Tenor H, Hatzelmann A, Church MK, et al. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-35.
28. Barnette MS, Christensen SB, Essayan DM, et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998;2B4:420-6.
29. Cohan VL, Showell HJ, Pazoles CJ, et al. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J Pharmacol Exp Ther 1996;278:1356-61.
30. Kaneko T, Alvarez R, Ueki IF, et al. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell Signal 1995;7:527-34.
31. Kohyama T, Liu X, Wen F, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 2002;26:694-701.
32. Culpitt SV, de Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1371-6.
33. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
34. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp 2001;234:169-85; discussion 185-8:169-85.
35. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.